ApprovedFDA approval

Isembyld (apitegromab-mstn)

Scholar Rock (SRRK)

Marketer take

An add-on for SMA patients already on SMN2-targeted therapy, so it sells alongside existing SMA brands rather than against them; neuromuscular centers and caregiver communities are the key audiences.

Sponsor company
Scholar Rock (SRRK)
Indication
To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment
Therapeutic area
Neurology, Rare disease
Event
FDA approval
Date
Sep 11, 2026
Status
Approved
Source
FDA page
Last verified
Nov 15, 2026

Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?

Get alerts when FDA dates move